. Author manuscript; available in PMC: 2016 Jan 14.

Published in final edited form as: Expert Opin Orphan Drugs. 2014 Aug 27;2(10):1063–1074. doi: 10.1517/21678707.2014.953481

Table 2.

Therapeutic Targeting in LAM

LAM Pathology/Target	Potential Drug
LAM Cell Growth	Sirolimus
	Everolimus
	New Generation mTOR inhibitors^*

LAM Cell Survival	Simvastatin
	Hydroxychloroquine

LAM Cell Migration	Simvastatin
	Saracatinib

Estrogen	Letrozole
	Fulvestrant (Faslodex)^*

Lymphangiogenesis	Pazpanib/axitinib^*
	Soluble VEGFR-3^*
	Anti-VEGF-D antibody^*

Matrix Degradation	Doxycycline
	Metalloproteinase inhibitors^*
	Cathepsin inhibitors^*

Endoplasmic Reticulum (ER) Stress	Bortezomib (Velcade)^*

Metabolic Reprogramming	Glucose/glutamine depravation^*
	Epigallocatechin gallate (EGCG)^*

Potential drugs of interest and therapeutic approaches which have not yet been tested